Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Share-based Compensation (2019 - 2025)

Eton Pharmaceuticals' Share-based Compensation history spans 7 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 54.18% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $5.2 million, up 7.84%, while the annual FY2024 figure was $3.2 million, 0.89% up from the prior year.
  • Share-based Compensation for Q3 2025 was $1.1 million at Eton Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.4 million in Q3 2024 and bottomed at $673000.0 in Q1 2021.
  • The 5-year median for Share-based Compensation is $872000.0 (2023), against an average of $1.0 million.
  • The largest annual shift saw Share-based Compensation soared 226.44% in 2024 before it plummeted 54.18% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $863000.0 in 2021, then increased by 2.67% to $886000.0 in 2022, then dropped by 15.35% to $750000.0 in 2023, then increased by 4.27% to $782000.0 in 2024, then skyrocketed by 39.64% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Share-based Compensation are $1.1 million (Q3 2025), $2.1 million (Q2 2025), and $1.2 million (Q1 2025).